Avagenesis Summarizes Milestones Achieved
Friday, 17 August 2018 05:40 PM
Avagenesis Corp. (TSXV: VVA) (“Avagenesis” or “Company”) summarizes its developmental milestones achieved.
The Company initiated the process of applying for its shares to be listed on the TSXV in September 2013 and its shares began trading in December 2013 (“IPO”). At that time, it had only recently achieved a successful proof of concept of the first prototype of its bioprocessing and cell isolation system (“System”).
The Company has since achieved the following:
- Initiated and completed the industrial design process for a second generation System for commercialization;
- Completed the second generation commercial prototype and manufacturing plan specifications;
- Recruited assembly resources and began sourcing and procuring plastic components, mechanical and electrical parts and components, control unit parts, circuit boards, intermediate assemblies and chassis components required for the bioprocessing systems;
- Secured an assembly location and completed the set up of an assembly facility. The initial Systems produced were used for testing purposes only and are now part of the development plan to advance the System to commercialization;
- Completed a third party performance validation study of its automated bioprocessing and stem cell isolation system, where the results confirmed that the System significantly outperforms competing systems in all metrics;
- Completed adjustments to the System’s design and assembly process based on feedback from clinics with commercial validation-deployed Systems;
- Registered with the U.S. Food and Drug Administration’s Center for Devices and Radiological Health, the Taiwan Food and Drug Administration and the South Korea Ministry of Food and Drug Safety for the licensed technology;
- Obtained and successfully re-certified under the Canadian Standards Association (“CSA”) Group certification while continuing to work on securing (among others) the European Conformity (“CE”) Mark;
- Obtained and successfully re-certified the quality management systems for the manufacturing of its System under ISO 13485 and 9001;
- Completed the development of the overall process for product packaging, shipping and tracking, as well as the initial development of manuals, training videos and user guides for the System;
- Expanded the exclusive worldwide licensed field of use from the initial cosmetic surgery (medical aesthetics) and research markets to include significantly larger overall worldwide markets of burn wound management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, hepatic and kidney disease;
- Received patent acceptance and/or notice of allowance letters for the licensed technology for the following jurisdictions: Singapore, Australia, United States of America, Republic of Korea (“South Korea”), Japan, Russia, China, Canada, Taiwan, and Israel. Some jurisdictions have issued multiple patents, for an additional separate patent family application related to the System;
- Finalized the standard operating protocol manuals, training videos and user guides for the System;
- Launched a Taiwan Sales Office, the Company’s first sales office in Asia, and also appointed a major South Korea medical products distributor to market the System in South Korea;
- Appointed a non-exclusive distributor of the System for the Federative Republic of Brazil (“Brazil”);
- Appointed an exclusive distributor of the System for northern India;
- Validation clinics have advised that over 100 patients have had successful procedures with our System, with no reported adverse events and that their patients are very satisfied with the results of the procedures that have been performed;
- Arranged seven active studies with Institutional Review Board (IRB) approvals for a multitude of indications, to advance[BR1] scientific and clinical application data, using the adipose stem cell isolation platform;
- Successfully and rapidly bioprocessed six clinical adipose stem cell cases using a single System in an eight hour period to validate the performance efficiency in a clinical setting;
- Installed multiple systems with the Company now being an approved supplier with one of the top three hospitals in the United States, as ranked by U.S. News & World Report’s “2015-16 Best Hospitals Honor Roll”;
- Completed a global collaboration agreement for distribution and marketing with Avapecia Life Sciences Corp. (CSE: VVS) to market under a common brand - Liberty Biopharma Inc.;
- Launched a new marketing website (libertybiopharma.com), which features a bright, modern interface and user-friendly navigational experience.
The Company’s stem cell platform is being positioned for research and clinical adoption by leading medical research organizations globally.
About Avagenesis Corp.
Avagenesis is a biotechnology company engaged in the commercialization of licensed cell isolation medical technologies for use in regenerative medical aesthetics, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, hepatic disease and kidney disease.
Neither the TSX Venture Exchange nor their respective regulation services providers (as that term is defined in their respective policies) accepts responsibility for the adequacy or accuracy of this press release.
Cautionary Statements
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", “likely”, "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that the Company may not successfully transition to a clinical stage company and successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Readers are cautioned that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
For further information, please contact:
Avagenesis Corp.
Alan Tam, CPA, CA
Chief Financial Officer
Telephone: (604) 377-7575
